I don't think anybody is doing anything as a result of the infringement lawsuit. Amarin isn't going to purposefully stall sales because another 10,000 to 20,000 scripts is all that's needed to point Amarin toward quarterly profits, which would get the stock price out of the mud.
The success of the infringement lawsuit will not be based on what percentage of the market the generics hold. They either infringed in their messaging in literature and online or they didn't. And how many scripts they stole could factor in damages, but, again, it has nothing to do with whether they infringed.
And Hikma has shown itself to be arrogant and pig headed and thinking it's above the law. So I think if they could steal 60 percent of Amarin's market, they'd do it in a heartbeat and leave it to their lawyers to argue that the switch to generic from Vascepa was the choice of states, insurance companies, doctors, patients and pharmacists rather than them.
Market Data 
Markets 
AI
